Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathan Fowler

Showing results (81-90 of 87) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 87 results.
JAMA Oncology|June 10, 2021
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 TrialNitin Jain, Michael Keating, Philip Thompson, et al.
Cancer Cell|August 9, 2022
Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomesAleksandr Zaitsev, Maksim Chelushkin, Daniiar Dyikanov, et al.
Blood Advances|March 20, 2020
Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCLPreetesh Jain, Shaojun Zhang, Rashmi Kanagal-Shamanna, et al.
American Journal of Hematology|April 3, 2020
Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patientsShuangtao Zhao, Rashmi Kanagal-Shamanna, Lucy Navsaria, et al.
The Lancet. Oncology|January 25, 2022
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trialMichael L Wang, Preetesh Jain, Shuangtao Zhao, et al.
Cancer Cell|March 1, 2024
Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patientsAndrea J Radtke, Ekaterina Postovalova, Arina Varlamova, et al.
Cancer Cell|May 14, 2024
Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancerDaniiar Dyikanov, Aleksandr Zaitsev, Tatiana Vasileva, et al.
Pageof 9

Showing results (81-90 of 87) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 87 results.
JAMA Oncology|June 10, 2021
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 TrialNitin Jain, Michael Keating, Philip Thompson, et al.
Cancer Cell|August 9, 2022
Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomesAleksandr Zaitsev, Maksim Chelushkin, Daniiar Dyikanov, et al.
Blood Advances|March 20, 2020
Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCLPreetesh Jain, Shaojun Zhang, Rashmi Kanagal-Shamanna, et al.
American Journal of Hematology|April 3, 2020
Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patientsShuangtao Zhao, Rashmi Kanagal-Shamanna, Lucy Navsaria, et al.
The Lancet. Oncology|January 25, 2022
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trialMichael L Wang, Preetesh Jain, Shuangtao Zhao, et al.
Cancer Cell|March 1, 2024
Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patientsAndrea J Radtke, Ekaterina Postovalova, Arina Varlamova, et al.
Cancer Cell|May 14, 2024
Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancerDaniiar Dyikanov, Aleksandr Zaitsev, Tatiana Vasileva, et al.
Pageof 9